Pfizer Asks High Court To Scrap Novartis Hemophilia Patents
A Pfizer Inc. unit on Tuesday asked the U.S. Supreme Court to consider its argument that the Federal Circuit had erred in upholding Novartis Vaccines & Diagnostics Inc.'s hemophilia drug patents...To view the full article, register now.
Already a subscriber? Click here to view full article